

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Leila Alland
Date of Last Notice:	9 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-														
Date of change	8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>1,900,002</td></tr></table>				Shares	Options	Direct	-	1,900,002	Indirect	-	-	Total	-	1,900,002
	Shares	Options													
Direct	-	1,900,002													
Indirect	-	-													
Total	-	1,900,002													
Class	Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>71,740</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>71,740</td><td>-</td></tr></table>				Shares	Options	Direct	71,740	-	Indirect	-	-	Total	71,740	-
	Shares	Options													
Direct	71,740	-													
Indirect	-	-													
Total	71,740	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.07 per share		
No. of securities held after change		Shares	Options
	Direct	71,740	1,900,002
	Indirect	-	-
	Total	71,740	1,900,002
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities via Entitlement Offer announced 31 October 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Michael Baker
Date of Last Notice:	2 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity														
Date of change	8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>45,983</td><td>6,260</td></tr><tr><td>Total</td><td>45,983</td><td>1,906,262</td></tr></table>				Shares	Options	Direct	-	1,900,002	Indirect	45,983	6,260	Total	45,983	1,906,262
	Shares	Options													
Direct	-	1,900,002													
Indirect	45,983	6,260													
Total	45,983	1,906,262													
Class	Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>71,428</td><td></td></tr><tr><td>Total</td><td>71,428</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	71,428		Total	71,428	-
	Shares	Options													
Direct	-	-													
Indirect	71,428														
Total	71,428	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.07 per share		
No. of securities held after change		Shares	Options
	Direct	-	1,900,002
	Indirect	117,411	6,260
	Total	117,411	1,906,262
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities via Entitlement Offer announced 31 October 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	7 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	a) Direct b) Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	b) Held via Broker nominee account														
Date of change	a) 14 December 2023 b) 8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>6,374,769</td><td>29,824,013</td></tr><tr><td>Indirect</td><td>350,000</td><td>-</td></tr><tr><td>Total</td><td>6,724,769</td><td>29,824,013</td></tr></table>				Shares	Options	Direct	6,374,769	29,824,013	Indirect	350,000	-	Total	6,724,769	29,824,013
	Shares	Options													
Direct	6,374,769	29,824,013													
Indirect	350,000	-													
Total	6,724,769	29,824,013													
Class	a & b) Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>a) 2,128,815</td><td>-</td></tr><tr><td>Indirect</td><td>b) 800,000</td><td>-</td></tr><tr><td>Total</td><td>2,928,815</td><td>-</td></tr></table>				Shares	Options	Direct	a) 2,128,815	-	Indirect	b) 800,000	-	Total	2,928,815	-
	Shares	Options													
Direct	a) 2,128,815	-													
Indirect	b) 800,000	-													
Total	2,928,815	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) \$0.105 per share b) \$0.07 per share		
No. of securities held after change		Shares	Options
	Direct	8,503,584	29,824,013
	Indirect	1,150,000	-
	Total	9,653,584	29,824,013
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) Issue of Forfeiture Shares in accordance with pre-employment contract. b) Issue of securities via Entitlement Offer announced 31 October 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Hester Larkin
Date of Last Notice:	9 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via Broker nominee account														
Date of change	8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>66,114</td><td>-</td></tr><tr><td>Total</td><td>66,114</td><td>1,900,002</td></tr></table>				Shares	Options	Direct	-	1,900,002	Indirect	66,114	-	Total	66,114	1,900,002
	Shares	Options													
Direct	-	1,900,002													
Indirect	66,114	-													
Total	66,114	1,900,002													
Class	Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>28,133</td><td>-</td></tr><tr><td>Total</td><td>28,133</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	28,133	-	Total	28,133	-
	Shares	Options													
Direct	-	-													
Indirect	28,133	-													
Total	28,133	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.07 per share		
No. of securities held after change		Shares	Options
	Direct	-	1,900,002
	Indirect	94,247	-
	Total	94,247	1,900,002
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities via Entitlement Offer announced 31 October 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	7 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-														
Date of change	8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>209,167</td><td>5,002,524</td></tr><tr><td>Indirect</td><td>590,833</td><td>70,422</td></tr><tr><td>Total</td><td>800,000</td><td>5,072,946</td></tr></table>				Shares	Options	Direct	209,167	5,002,524	Indirect	590,833	70,422	Total	800,000	5,072,946
	Shares	Options													
Direct	209,167	5,002,524													
Indirect	590,833	70,422													
Total	800,000	5,072,946													
Class	Fully Paid Ordinary Shares														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>71,428</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>71,428</td><td>-</td></tr></table>				Shares	Options	Direct	71,428	-	Indirect	-	-	Total	71,428	-
	Shares	Options													
Direct	71,428	-													
Indirect	-	-													
Total	71,428	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.07 per share		
No. of securities held after change		Shares	Options
	Direct	280,595	5,002,524
	Indirect	590,833	70,422
	Total	871,428	5,072,946
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities via Entitlement Offer announced 31 October 2023.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.